APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Ovarian Reserve Testing

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Ovarian Reserve Testing Market Outlook and Growth Opportunities 2026

Report ID 174021220431 December 2025192 pages

Choose your research edition.

Industry ResearchOvarian Reserve Testing Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Ovarian Reserve Testing Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Ovarian Reserve Testing Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Ovarian Reserve Testing Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Ovarian Reserve Testing Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Ovarian Reserve Testing market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Ovarian Reserve Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Ovarian Reserve Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Ovarian Reserve Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Ovarian Reserve Testing market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Ovarian Reserve Testing market include VIDAS, Modern Fertility, LetsGetChecked, LabCorp, Future Family, Fujirebio, F. Hoffmann-La Roche Ltd, Everlywell and EggQ, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Ovarian Reserve Testing market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Ovarian Reserve Testing and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Ovarian Reserve Testing revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Ovarian Reserve Testing market.

Ovarian Reserve Testing Segment by Company

VIDAS

Modern Fertility

LetsGetChecked

LabCorp

Future Family

Fujirebio

F. Hoffmann-La Roche Ltd

Everlywell

EggQ

Beckman Coulter

Ovarian Reserve Testing Segment by Type

Follicle Stimulating Hormone (FSH) Testing

Antral Follicle Count Testing

Basal Follicle Stimulating Hormone Testing

Anti-Mullerian hormone (AMH) Testing

Ovarian Reserve Testing Segment by Application

Hospital

Clinic

Ovarian Reserve Testing Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Ovarian Reserve Testing status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Ovarian Reserve Testing key companies, revenue, market share, and recent developments.

3. To split the Ovarian Reserve Testing breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Ovarian Reserve Testing market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Ovarian Reserve Testing significant trends, drivers, influence factors in global and regions.

6. To analyze Ovarian Reserve Testing competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ovarian Reserve Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Ovarian Reserve Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ovarian Reserve Testing.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Ovarian Reserve Testing industry.

Chapter 3: Detailed analysis of Ovarian Reserve Testing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Ovarian Reserve Testing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Ovarian Reserve Testing in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Ovarian Reserve Testing Industry Trends Table 2. Ovarian Reserve Testing Industry Drivers Table 3. Ovarian Reserve Testing Industry Opportunities and Challenges Table 4. Ovarian Reserve Testing Industry Restraints Table 5. Global Ovarian Reserve Testing Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Ovarian Reserve Testing Revenue Share by Company (2021-2026) Table 7. Global Ovarian Reserve Testing Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Ovarian Reserve Testing Key Company Manufacturing Base & Headquarters Table 9. Global Ovarian Reserve Testing Company, Product Type & Application Table 10. Global Ovarian Reserve Testing Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Ovarian Reserve Testing by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Follicle Stimulating Hormone (FSH) Testing Table 15. Significant Companies of Antral Follicle Count Testing Table 16. Significant Companies of Basal Follicle Stimulating Hormone Testing Table 17. Significant Companies of Anti-Mullerian hormone (AMH) Testing Table 18. Global Ovarian Reserve Testing Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Ovarian Reserve Testing Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Ovarian Reserve Testing Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Ovarian Reserve Testing Sales Value Share by Type (2021-2026) Table 22. Global Ovarian Reserve Testing Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Hospital Table 24. Significant Companies of Clinic Table 25. Global Ovarian Reserve Testing Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Ovarian Reserve Testing Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Ovarian Reserve Testing Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Ovarian Reserve Testing Sales Value Share by Application (2021-2026) Table 29. Global Ovarian Reserve Testing Sales Value Share by Application (2027-2032) Table 30. Global Ovarian Reserve Testing Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Ovarian Reserve Testing Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Ovarian Reserve Testing Sales Value Share by Region (2021-2026) Table 33. Global Ovarian Reserve Testing Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Ovarian Reserve Testing Sales Value Share by Region (2027-2032) Table 35. Global Ovarian Reserve Testing Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Ovarian Reserve Testing Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Ovarian Reserve Testing Sales Value Market Share by Country (2021-2026) Table 38. Global Ovarian Reserve Testing Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Ovarian Reserve Testing Sales Value Market Share by Country (2027-2032) Table 40. VIDAS Company Information Table 41. VIDAS Business Overview Table 42. VIDAS Ovarian Reserve Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. VIDAS Ovarian Reserve Testing Product Portfolio Table 44. VIDAS Recent Development Table 45. Modern Fertility Company Information Table 46. Modern Fertility Business Overview Table 47. Modern Fertility Ovarian Reserve Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Modern Fertility Ovarian Reserve Testing Product Portfolio Table 49. Modern Fertility Recent Development Table 50. LetsGetChecked Company Information Table 51. LetsGetChecked Business Overview Table 52. LetsGetChecked Ovarian Reserve Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. LetsGetChecked Ovarian Reserve Testing Product Portfolio Table 54. LetsGetChecked Recent Development Table 55. LabCorp Company Information Table 56. LabCorp Business Overview Table 57. LabCorp Ovarian Reserve Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. LabCorp Ovarian Reserve Testing Product Portfolio Table 59. LabCorp Recent Development Table 60. Future Family Company Information Table 61. Future Family Business Overview Table 62. Future Family Ovarian Reserve Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Future Family Ovarian Reserve Testing Product Portfolio Table 64. Future Family Recent Development Table 65. Fujirebio Company Information Table 66. Fujirebio Business Overview Table 67. Fujirebio Ovarian Reserve Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Fujirebio Ovarian Reserve Testing Product Portfolio Table 69. Fujirebio Recent Development Table 70. F. Hoffmann-La Roche Ltd Company Information Table 71. F. Hoffmann-La Roche Ltd Business Overview Table 72. F. Hoffmann-La Roche Ltd Ovarian Reserve Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. F. Hoffmann-La Roche Ltd Ovarian Reserve Testing Product Portfolio Table 74. F. Hoffmann-La Roche Ltd Recent Development Table 75. Everlywell Company Information Table 76. Everlywell Business Overview Table 77. Everlywell Ovarian Reserve Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Everlywell Ovarian Reserve Testing Product Portfolio Table 79. Everlywell Recent Development Table 80. EggQ Company Information Table 81. EggQ Business Overview Table 82. EggQ Ovarian Reserve Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. EggQ Ovarian Reserve Testing Product Portfolio Table 84. EggQ Recent Development Table 85. Beckman Coulter Company Information Table 86. Beckman Coulter Business Overview Table 87. Beckman Coulter Ovarian Reserve Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Beckman Coulter Ovarian Reserve Testing Product Portfolio Table 89. Beckman Coulter Recent Development Table 90. Research Programs/Design for This Report Table 91. Authors List of This Report Table 92. Secondary Sources Table 93. Primary Sources List of Figures Figure 1. Ovarian Reserve Testing Product Image Figure 2. Global Ovarian Reserve Testing Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Ovarian Reserve Testing Market Size (2021-2032) & (US$ Million) Figure 4. Global Ovarian Reserve Testing Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Follicle Stimulating Hormone (FSH) Testing Image Figure 8. Antral Follicle Count Testing Image Figure 9. Basal Follicle Stimulating Hormone Testing Image Figure 10. Anti-Mullerian hormone (AMH) Testing Image Figure 11. Global Ovarian Reserve Testing Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Ovarian Reserve Testing Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Ovarian Reserve Testing Sales Value Share by Type (2021-2032) Figure 14. Hospital Image Figure 15. Clinic Image Figure 16. Global Ovarian Reserve Testing Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Ovarian Reserve Testing Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Ovarian Reserve Testing Sales Value Share by Application (2021-2032) Figure 19. Global Ovarian Reserve Testing Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Ovarian Reserve Testing Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Ovarian Reserve Testing Sales Value (2021-2032) & (US$ Million) Figure 22. North America Ovarian Reserve Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Ovarian Reserve Testing Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Ovarian Reserve Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Ovarian Reserve Testing Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Ovarian Reserve Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Ovarian Reserve Testing Sales Value (2021-2032) & (US$ Million) Figure 28. South America Ovarian Reserve Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Ovarian Reserve Testing Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Ovarian Reserve Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Ovarian Reserve Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Ovarian Reserve Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Ovarian Reserve Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Ovarian Reserve Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Ovarian Reserve Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Ovarian Reserve Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Ovarian Reserve Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Ovarian Reserve Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Ovarian Reserve Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Ovarian Reserve Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Ovarian Reserve Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Ovarian Reserve Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Ovarian Reserve Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Ovarian Reserve Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Ovarian Reserve Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Ovarian Reserve Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Ovarian Reserve Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Ovarian Reserve Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Ovarian Reserve Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Ovarian Reserve Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Ovarian Reserve Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Ovarian Reserve Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Ovarian Reserve Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Ovarian Reserve Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Ovarian Reserve Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Ovarian Reserve Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Ovarian Reserve Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Ovarian Reserve Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Follicle Stimulating Hormone (FSH) Testing
  • Antral Follicle Count Testing
  • Basal Follicle Stimulating Hormone Testing
  • Anti-Mullerian hormone (AMH) Testing
Applications
  • Hospital
  • Clinic
Companies covered
  • VIDAS
  • Modern Fertility
  • LetsGetChecked
  • LabCorp
  • Future Family
  • Fujirebio
  • F. Hoffmann-La Roche Ltd
  • Everlywell
  • EggQ
  • Beckman Coulter

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Ovarian Reserve Testing Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Ovarian Reserve Testing Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Ovarian Reserve Testing Market Dynamics
  1. 2.1 Ovarian Reserve Testing Industry Trends
  2. 2.2 Ovarian Reserve Testing Industry Drivers
  3. 2.3 Ovarian Reserve Testing Industry Opportunities and Challenges
  4. 2.4 Ovarian Reserve Testing Industry Restraints
3 Ovarian Reserve Testing Market by Company
  1. 3.1 Global Ovarian Reserve Testing Company Revenue Ranking in 2025
  2. 3.2 Global Ovarian Reserve Testing Revenue by Company (2021-2026)
  3. 3.3 Global Ovarian Reserve Testing Company Ranking (2024-2026)
  4. 3.4 Global Ovarian Reserve Testing Company Manufacturing Base and Headquarters
  5. 3.5 Global Ovarian Reserve Testing Company Product Type and Application
  6. 3.6 Global Ovarian Reserve Testing Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Ovarian Reserve Testing Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Ovarian Reserve Testing Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Ovarian Reserve Testing Market by Type
  1. 4.1 Ovarian Reserve Testing Type Introduction
  2. 4.1.1 Follicle Stimulating Hormone (FSH) Testing
  3. 4.1.2 Antral Follicle Count Testing
  4. 4.1.3 Basal Follicle Stimulating Hormone Testing
  5. 4.1.4 Anti-Mullerian hormone (AMH) Testing
  6. 4.2 Global Ovarian Reserve Testing Sales Value by Type
  7. 4.2.1 Global Ovarian Reserve Testing Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Ovarian Reserve Testing Sales Value by Type (2021-2032)
  9. 4.2.3 Global Ovarian Reserve Testing Sales Value Share by Type (2021-2032)
5 Ovarian Reserve Testing Market by Application
  1. 5.1 Ovarian Reserve Testing Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.2 Global Ovarian Reserve Testing Sales Value by Application
  5. 5.2.1 Global Ovarian Reserve Testing Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Ovarian Reserve Testing Sales Value by Application (2021-2032)
  7. 5.2.3 Global Ovarian Reserve Testing Sales Value Share by Application (2021-2032)
6 Ovarian Reserve Testing Regional Value Analysis
  1. 6.1 Global Ovarian Reserve Testing Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Ovarian Reserve Testing Sales Value by Region (2021-2032)
  3. 6.2.1 Global Ovarian Reserve Testing Sales Value by Region: 2021-2026
  4. 6.2.2 Global Ovarian Reserve Testing Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Ovarian Reserve Testing Sales Value (2021-2032)
  7. 6.3.2 North America Ovarian Reserve Testing Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Ovarian Reserve Testing Sales Value (2021-2032)
  10. 6.4.2 Europe Ovarian Reserve Testing Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Ovarian Reserve Testing Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Ovarian Reserve Testing Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Ovarian Reserve Testing Sales Value (2021-2032)
  16. 6.6.2 South America Ovarian Reserve Testing Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Ovarian Reserve Testing Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Ovarian Reserve Testing Sales Value Share by Country, 2025 VS 2032
7 Ovarian Reserve Testing Country-level Value Analysis
  1. 7.1 Global Ovarian Reserve Testing Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Ovarian Reserve Testing Sales Value by Country (2021-2032)
  3. 7.2.1 Global Ovarian Reserve Testing Sales Value by Country (2021-2026)
  4. 7.2.2 Global Ovarian Reserve Testing Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Ovarian Reserve Testing Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Ovarian Reserve Testing Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Ovarian Reserve Testing Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Ovarian Reserve Testing Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Ovarian Reserve Testing Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Ovarian Reserve Testing Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Ovarian Reserve Testing Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Ovarian Reserve Testing Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Ovarian Reserve Testing Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Ovarian Reserve Testing Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Ovarian Reserve Testing Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Ovarian Reserve Testing Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Ovarian Reserve Testing Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Ovarian Reserve Testing Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Ovarian Reserve Testing Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Ovarian Reserve Testing Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Ovarian Reserve Testing Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Ovarian Reserve Testing Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Ovarian Reserve Testing Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Ovarian Reserve Testing Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Ovarian Reserve Testing Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Ovarian Reserve Testing Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Ovarian Reserve Testing Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Ovarian Reserve Testing Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Ovarian Reserve Testing Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Ovarian Reserve Testing Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Ovarian Reserve Testing Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Ovarian Reserve Testing Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Ovarian Reserve Testing Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Ovarian Reserve Testing Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 VIDAS
  2. 8.1.1 VIDAS Company Information
  3. 8.1.2 VIDAS Business Overview
  4. 8.1.3 VIDAS Ovarian Reserve Testing Revenue and Gross Margin (2021-2026)
  5. 8.1.4 VIDAS Ovarian Reserve Testing Product Portfolio
  6. 8.1.5 VIDAS Recent Developments
  7. 8.2 Modern Fertility
  8. 8.2.1 Modern Fertility Company Information
  9. 8.2.2 Modern Fertility Business Overview
  10. 8.2.3 Modern Fertility Ovarian Reserve Testing Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Modern Fertility Ovarian Reserve Testing Product Portfolio
  12. 8.2.5 Modern Fertility Recent Developments
  13. 8.3 LetsGetChecked
  14. 8.3.1 LetsGetChecked Company Information
  15. 8.3.2 LetsGetChecked Business Overview
  16. 8.3.3 LetsGetChecked Ovarian Reserve Testing Revenue and Gross Margin (2021-2026)
  17. 8.3.4 LetsGetChecked Ovarian Reserve Testing Product Portfolio
  18. 8.3.5 LetsGetChecked Recent Developments
  19. 8.4 LabCorp
  20. 8.4.1 LabCorp Company Information
  21. 8.4.2 LabCorp Business Overview
  22. 8.4.3 LabCorp Ovarian Reserve Testing Revenue and Gross Margin (2021-2026)
  23. 8.4.4 LabCorp Ovarian Reserve Testing Product Portfolio
  24. 8.4.5 LabCorp Recent Developments
  25. 8.5 Future Family
  26. 8.5.1 Future Family Company Information
  27. 8.5.2 Future Family Business Overview
  28. 8.5.3 Future Family Ovarian Reserve Testing Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Future Family Ovarian Reserve Testing Product Portfolio
  30. 8.5.5 Future Family Recent Developments
  31. 8.6 Fujirebio
  32. 8.6.1 Fujirebio Company Information
  33. 8.6.2 Fujirebio Business Overview
  34. 8.6.3 Fujirebio Ovarian Reserve Testing Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Fujirebio Ovarian Reserve Testing Product Portfolio
  36. 8.6.5 Fujirebio Recent Developments
  37. 8.7 F. Hoffmann-La Roche Ltd
  38. 8.7.1 F. Hoffmann-La Roche Ltd Company Information
  39. 8.7.2 F. Hoffmann-La Roche Ltd Business Overview
  40. 8.7.3 F. Hoffmann-La Roche Ltd Ovarian Reserve Testing Revenue and Gross Margin (2021-2026)
  41. 8.7.4 F. Hoffmann-La Roche Ltd Ovarian Reserve Testing Product Portfolio
  42. 8.7.5 F. Hoffmann-La Roche Ltd Recent Developments
  43. 8.8 Everlywell
  44. 8.8.1 Everlywell Company Information
  45. 8.8.2 Everlywell Business Overview
  46. 8.8.3 Everlywell Ovarian Reserve Testing Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Everlywell Ovarian Reserve Testing Product Portfolio
  48. 8.8.5 Everlywell Recent Developments
  49. 8.9 EggQ
  50. 8.9.1 EggQ Company Information
  51. 8.9.2 EggQ Business Overview
  52. 8.9.3 EggQ Ovarian Reserve Testing Revenue and Gross Margin (2021-2026)
  53. 8.9.4 EggQ Ovarian Reserve Testing Product Portfolio
  54. 8.9.5 EggQ Recent Developments
  55. 8.10 Beckman Coulter
  56. 8.10.1 Beckman Coulter Company Information
  57. 8.10.2 Beckman Coulter Business Overview
  58. 8.10.3 Beckman Coulter Ovarian Reserve Testing Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Beckman Coulter Ovarian Reserve Testing Product Portfolio
  60. 8.10.5 Beckman Coulter Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst